hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06385600, orgStudyIdInfo id: severe preeclampsia, briefTitle: Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-20, primaryCompletionDateStruct date: 2026-01-20, completionDateStruct date: 2026-03-20, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: The only effective treatment of severe preeclampsia is delivery of the fetus but immediate antihypertensive treatment is given to stabilize the patient and prevent further complications. All antihypertensive medication can potentially cross the placenta. At this time, there are no randomized control trials to base a recommendation for the use of one antihypertensive agent over another. However, certain medications are effective in lowering blood pressure with an acceptable safety profile in pregnancy. The choice of therapy depends on the acuity and severity of hypertension, conditionsModule conditions: Severe Pre-eclampsia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Labetalol, interventions name: Phentolamine, outcomesModule primaryOutcomes measure: the effect of Labetalol and Phentolamine on MCA flow velocity by transcranial Doppler monitoring., secondaryOutcomes measure: The effect of labetalol and phentolamine on blood pressure of the patients, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06385587, orgStudyIdInfo id: ADH-OL-Study-01-23, briefTitle: Technology-based Symptom Monitoring Intervention for Locally Advanced Head and Neck Cancer Patients, acronym: SYMTECH01, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-03, primaryCompletionDateStruct date: 2024-12-29, completionDateStruct date: 2025-09-27, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Aptar Digital Health, class: INDUSTRY, descriptionModule briefSummary: The goal of this observational study is to assess the satisfaction and usability of an interactive and patient-centered mobile application (app), Oleena™, designed to assist head and neck cancer patients undergoing chemoradiation in managing common and distressing symptoms in real-time, as well as to assess the satisfaction and usability of the related HCP web portal. Additional secondary usage and clinical endpoints that would be used to assess intervention efficacy in future trials will be collected., conditionsModule conditions: Head and Neck Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Oleena, outcomesModule primaryOutcomes measure: Users' satisfaction, secondaryOutcomes measure: Feasibility of the technology enabled symptom management solution, secondaryOutcomes measure: Usability of the technology enabled symptom management solution, secondaryOutcomes measure: Appropriateness of the recommendations, secondaryOutcomes measure: Semi-structured exit interviews, otherOutcomes measure: Symptom burden will be measured using the NIH PRO-CTCAE measurement system, which includes validated scales for individual toxicities, otherOutcomes measure: Quality of life will be measured using the previously validated FACT-G scale, otherOutcomes measure: Treatment adherence, otherOutcomes measure: Health-economic outcome, otherOutcomes measure: Complaints, alleged deficiencies or malfunctions of the device reported, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06385574, orgStudyIdInfo id: 2023-088, briefTitle: Technological Based Rehabilitation on Individuals With Rheumatic Disease, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-05-15, completionDateStruct date: 2024-05-20, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Akdeniz University, class: OTHER, descriptionModule briefSummary: Affects such as pain, swelling, tenderness, deformities, limitations, strength and function losses, skill and coordination deficiencies in the hand joints, which are frequently seen in rheumatism patients with hand involvement, are included in body structure and function disorders within the framework of International Classification of Function System. Leap Motion Controller is used in hand rehabilitation because it is small in size, low-cost, portable, non-contact, easy to use and provides visual and auditory feedback. The aim of our study is to examine the effect of technology-based rehabilitation on joint range of motion, grip strength, functionality and disease activity in adult individuals with rheumatic disease with hand involvement; and also to compare these effects with the effects of the hand rehabilitation program implemented under the guidance of a physiotherapist and the control group that continues its routine life., conditionsModule conditions: Rheumatic Diseases, conditions: Hand Rheumatism, conditions: Virtual Reality Therapy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: There are three groups in the study. First group is leap motion interventional group, second group is hand exercises group and the third group is waiting list., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Investigator and outcome assessors do not know which patient is in which group., whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: Virtual reality therapy, outcomesModule primaryOutcomes measure: Hand grip strength measurement, primaryOutcomes measure: Jebsen Hand Function Test (JHFT), primaryOutcomes measure: Nine Hole Peg Test (NHPT), primaryOutcomes measure: Duruoz Hand Index (DHI), primaryOutcomes measure: Michigan Hand Outcome questionnaire (MHQ), secondaryOutcomes measure: Disease Activity Score 28 (DAS 28), secondaryOutcomes measure: Hand fine grip strength measurement, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 64 Years, stdAges: ADULT, contactsLocationsModule locations facility: Sebahat Yaprak Cetin, status: RECRUITING, city: Antalya, state: Konyaaltı, zip: 07100, country: Turkey, contacts name: Sebahat Yaprak Cetin, PhD, role: CONTACT, email: fzt.ycetin@gmail.com, geoPoint lat: 36.90812, lon: 30.69556, hasResults: False
protocolSection identificationModule nctId: NCT06385561, orgStudyIdInfo id: Tramadol_OIBD, secondaryIdInfos id: 2022-500108-23-00, type: CTIS, briefTitle: The Influence of Tramadol on Opioid-induced Bowel Dysfunction, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-08-11, primaryCompletionDateStruct date: 2023-05-15, completionDateStruct date: 2023-05-15, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Asbjørn Mohr Drewes, class: OTHER, descriptionModule briefSummary: Tramadol is a weak opioid and widely used to treat moderate to severe pain. Stronger opioids are known to inhibit gastrointestinal motility and secretion, however the effects of tramadol on gastrointestinal function remains less understood. The aim of this study was to determine to what degree tramadol causes opioid-induced bowel dysfunction by using an objective design to explore gastrointestinal transit, motility pattern, secretion, and colonic volume, in a group of healthy male volunteers., conditionsModule conditions: Opioid-Induced Bowel Dysfunction, conditions: Constipation, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: Tramadol, interventions name: Placebo, outcomesModule primaryOutcomes measure: Total gastrointestinal transit time, primaryOutcomes measure: Colorectal transit time, secondaryOutcomes measure: Constipation symptoms, secondaryOutcomes measure: Bowel movement frequency, secondaryOutcomes measure: Stool consistency, secondaryOutcomes measure: Gastrointestinal symptoms, secondaryOutcomes measure: Opioid-induced constipation, secondaryOutcomes measure: Diagnostic evaluation of opioid-induced constipation, secondaryOutcomes measure: Colonic motility patterns, secondaryOutcomes measure: Opiate withdrawal symptoms, secondaryOutcomes measure: Colon volume, secondaryOutcomes measure: Colonic water content, secondaryOutcomes measure: Gastric half emptying time, secondaryOutcomes measure: Gastric contraction assessment, secondaryOutcomes measure: Gastric contraction assessment, secondaryOutcomes measure: Small bowel motility assessment, secondaryOutcomes measure: Small bowel water content, eligibilityModule sex: MALE, minimumAge: 20 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Aalborg University Hospital, city: Aalborg, zip: 9000, country: Denmark, geoPoint lat: 57.048, lon: 9.9187, hasResults: False
protocolSection identificationModule nctId: NCT06385509, orgStudyIdInfo id: TOL-CLAR-20024, briefTitle: A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-10, completionDateStruct date: 2026-02, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Tolmar Inc., class: INDUSTRY, collaborators name: ICON plc, descriptionModule briefSummary: TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months., conditionsModule conditions: Hypogonadism, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: Jatenzo, outcomesModule primaryOutcomes measure: CST Test, secondaryOutcomes measure: Adrenal Insufficiency, otherOutcomes measure: Estrogen changes, otherOutcomes measure: Follicle Stimulating Hormone (FSH) changes., otherOutcomes measure: Luteinizing hormone (LH) changes, otherOutcomes measure: Sperm analysis, otherOutcomes measure: Sperm analysis, otherOutcomes measure: Sperm analysis, otherOutcomes measure: Testis volume analysis, eligibilityModule sex: MALE, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06385496, orgStudyIdInfo id: NCI-2024-01145, secondaryIdInfos id: NCI-2024-01145, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: EAY131-L, secondaryIdInfos id: EAY131-L, type: OTHER, domain: ECOG-ACRIN Cancer Research Group, secondaryIdInfos id: EAY131-L, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180820, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180820, briefTitle: Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2017-03-12, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II MATCH treatment trial tests how well MLN0128 (TAK-228) works in treating patients with cancer that has certain genetic changes called mTOR mutations. MLN0128 (TAK-228) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth., conditionsModule conditions: Advanced Lymphoma, conditions: Advanced Malignant Solid Neoplasm, conditions: Refractory Lymphoma, conditions: Refractory Malignant Solid Neoplasm, conditions: Refractory Multiple Myeloma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Computed Tomography, interventions name: Magnetic Resonance Imaging, interventions name: Sapanisertib, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: 6-month progression free survival (PFS), secondaryOutcomes measure: Progression free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ECOG-ACRIN Cancer Research Group, city: Philadelphia, state: Pennsylvania, zip: 19103, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06385483, orgStudyIdInfo id: NCI-2024-01125, secondaryIdInfos id: NCI-2024-01125, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: EAY131-A, type: OTHER, domain: ECOG-ACRIN Cancer Research Group, secondaryIdInfos id: EAY131-A, type: OTHER, domain: CTEP, secondaryIdInfos id: U10CA180820, type: NIH, link: https://reporter.nih.gov/quickSearch/U10CA180820, briefTitle: Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A), statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2015-08-11, primaryCompletionDateStruct date: 2024-12-06, completionDateStruct date: 2024-12-06, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: National Cancer Institute (NCI), class: NIH, descriptionModule briefSummary: This phase II MATCH treatment trial tests how well afatinib works in treating patients with cancer that has certain genetic changes. Afatinib is in a class of medications called kinase inhibitors. It is used in patients whose cancer has a certain mutation (change) in the EGFR gene. It works by blocking the action of mutated EGFR that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells., conditionsModule conditions: Advanced Lymphoma, conditions: Advanced Malignant Solid Neoplasm, conditions: Refractory Lymphoma, conditions: Refractory Malignant Solid Neoplasm, conditions: Refractory Multiple Myeloma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: Afatinib, interventions name: Biopsy, interventions name: Biospecimen Collection, interventions name: Computed Tomography, interventions name: Echocardiography, interventions name: Magnetic Resonance Imaging, interventions name: Radionuclide Imaging, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: 6-month progression free survival (PFS), secondaryOutcomes measure: Progression free survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: ECOG-ACRIN Cancer Research Group, city: Philadelphia, state: Pennsylvania, zip: 19103, country: United States, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False
protocolSection identificationModule nctId: NCT06385470, orgStudyIdInfo id: HSEARS20231112001, briefTitle: Treatment of Cantonese Speakers With Childhood Apraxia of Speech, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2024-08-01, completionDateStruct date: 2025-02-01, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: The Hong Kong Polytechnic University, class: OTHER, collaborators name: University of Vermont, collaborators name: The University of Hong Kong, descriptionModule briefSummary: The proposed study aims to investigate the efficacy of the Dynamic Temporal and Tactile Cueing treatment in Cantonese-English bilingual speakers with childhood apraxia of speech., conditionsModule conditions: Childhood Apraxia of Speech, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 4, type: ESTIMATED, armsInterventionsModule interventions name: Dynamic Temporal and Tactile Cueing treatment, outcomesModule primaryOutcomes measure: Phonemes accuracy, primaryOutcomes measure: Stress accuracy, primaryOutcomes measure: Tone accuracy, eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 11 Years, stdAges: CHILD, contactsLocationsModule locations facility: The Hong Kong Polytechnic University, status: RECRUITING, city: Kowloon, country: Hong Kong, contacts name: Min Ney Wong, PhD, role: CONTACT, phone: +852 2766 7268, email: min.wong@polyu.edu.hk, geoPoint lat: 22.31667, lon: 114.18333, hasResults: False
protocolSection identificationModule nctId: NCT06385444, orgStudyIdInfo id: 2024-HS-020, briefTitle: IVF Failure and Pregnancy Loss on Couples' Psychological Stress, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: The First Hospital of Jilin University, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to learn about The purpose of this study was to compare the psychological differences between couples after IVF transplant failure and IVF pregnancy loss, including the differences in anxiety, depression, stress and post-traumatic stress between women and their spouses. The main question it aims to answer is:What are the psychological effects of IVF implantation failure and IVF pregnancy loss on women and the psychological differences between couples? Participants already taking IVF as part of their regular medical care will answer online survey questions about their joint pain for 1 years., conditionsModule conditions: Fertilization in Vitro, conditions: Pregnancy Loss, conditions: Psychological Stress, conditions: Post-traumatic Stress, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: As the number of failed IVF implants increases, does it increase the difference in anxiety and depression between couples?, primaryOutcomes measure: As the number of failed IVF implants increases, does it increase the difference in fertility stress between couples?, primaryOutcomes measure: Does pregnancy loss after IVF transplantation have a differential effect on anxiety and depression between couples?, primaryOutcomes measure: Does pregnancy loss after IVF transplantation have a differential effect on post-traumatic stress responses between couples?, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: the first hospital of Jilin University, city: Chang chun, state: Jilin, zip: 130000, country: China, contacts name: Qi Xi, doctorate, role: CONTACT, phone: 15804303801, email: xiqi@jlu.edu.cn, geoPoint lat: 42.74694, lon: 126.24667, hasResults: False
protocolSection identificationModule nctId: NCT06385431, orgStudyIdInfo id: Charm, briefTitle: Obeservational Cohort for Evaluating Future Cardiovascular Disease With High Metabolic Risks, acronym: Charm, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-28, primaryCompletionDateStruct date: 2026-04-30, completionDateStruct date: 2026-04-30, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, descriptionModule briefSummary: Cardiovascular and metabolic diseases refer to a large category of cardiovascular diseases accompanied by a series of metabolic disorders (including dyslipidemia, obesity, abnormal glucose tolerance, diabetes, hypertension, thyroid dysfunction, etc.), which is the primary cause of death and disease burden of Chinese residents.The number of deaths from atherosclerotic cardiovascular disease (ASCVD) in China is about 2.4 million, accounting for 61% of the total cardiovascular deaths, accounting for more than 40% of the all-cause deaths. In Chinese patients with coronary heart disease, 52.9% are complicated with diabetes.Despite the 1.1 million coronary stents implanted in China, there has been no reduction in cardiovascular mortality, which highlights the importance of threshold advancement and the management of metabolic risk factors.In recent years, the new concept of cardiovascular and metabolic diseases has been actively promoted at home and abroad, and the focus of prevention and treatment strategy of cardiovascular and metabolic diseases has been called for.The project proposed the concept of co-treatment of metabolic diseases based on disorders of blood pressure regulation, disorders of glucose metabolism and disorders of lipid metabolism. Subjects eligible for cardiovascular and metabolic diseases were screened, their past medical records were registered, education and diagnosis and treatment management were conducted., conditionsModule conditions: Metabolic Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 8000, type: ESTIMATED, armsInterventionsModule interventions name: observational study, outcomesModule primaryOutcomes measure: incidence rate of cardiovascular and metabolic diseases, primaryOutcomes measure: treatment rate of cardiovascular and metabolic diseases, primaryOutcomes measure: control rate of cardiovascular and metabolic diseases., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False